Please use this identifier to cite or link to this item:
Title: New Multitarget Hybrids Bearing Tacrine and Phenylbenzothiazole Motifs as Potential Drug Candidates for Alzheimer's Disease
Authors: Rajeshwari, Rajeshwari
Chand, Karam
Candeias, Emanuel 
Cardoso, Sandra M. 
Chaves, Sílvia
Santos, M. Amélia
Keywords: Alzheimer’s disease; Aβ aggregation; acetylcholinesterase inhibitors; benzothiazole; multitarget; tacrine hybrids
Issue Date: 7-Feb-2019
Publisher: MDPI
Project: UID/QUO/ 00100/2013 
Serial title, monograph or event: Molecules
Volume: 24
Issue: 3
Abstract: Research on neurodegenerative brain disorders, namely the age-dependent Alzheimer's disease (AD), has been intensified in the last decade due to the absence of a cure and the recognized increasing of life expectancy for populations. To address the multifactorial nature and complexity of AD, a multi-target-directed ligand approach was herein employed, by designing a set of six selected hybrids (14⁻19) that combine in the same entity two pharmacophores: tacrine (TAC) and 2-phenylbenzothiazole (PhBTA). The compounds contain a methoxy substituent at the PhBTA moiety and have a variable length linker between that and the TAC moiety. The docking studies showed that all the compounds assure a dual-binding mode of acetylcholinesterase (AChE) inhibition, establishing π-stacking and H-bond interactions with aminoacid residues at both active binding sites of the enzyme (CAS and PAS). The bioassays revealed that the designed compounds display excellent AChE inhibitory activity in the sub-micromolar range (0.06⁻0.27 μM) and moderate inhibition values for amyloid-β (Aβ) self-aggregation (27⁻44.6%), compounds 14 and 15 being the lead compounds. Regarding neuroprotective effects in neuroblastoma cells, compounds 15, 16 and 19 revealed the capacity to prevent Aβ-induced toxicity, but compound 16 showed the highest neuroprotective effect. Overall these hybrid compounds, in particular 15 and 16, with promising multitarget anti-AD ability, encourage further pursuing studies on this type of TAC-PhBTA derivatives for potential AD therapy.
ISSN: 1420-3049
DOI: 10.3390/molecules24030587
Rights: openAccess
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais
I&D CNC - Artigos em Revistas Internacionais

Show full item record


checked on Apr 22, 2024


checked on Apr 2, 2024

Page view(s)

checked on Apr 16, 2024


checked on Apr 16, 2024

Google ScholarTM




This item is licensed under a Creative Commons License Creative Commons